Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 329 clinical trials
MILESTONE-CD -A Prospective Multiomic Inception Real -Life Study To Evaluate Predictors of Disease Outcomes & respoNse to Biologic Treatment in Crohn's Disease

Crohn's' disease (CD) is a lifelong-chronic inflammatory condition of the digestive tract. CD frequently manifests during the 2nd or 3rd decade; prolonged disease duration frequently results in

  • 0 views
  • 28 Mar, 2021
  • 1 location
Defining Predictors of RT Response to Vedolizumab in IBD

The overall goal of the study is to develop data that can convincingly guide clinicians on the use and efficacy of vedolizumab in patients with small bowel CD. There is an unmet need to identify response to vedolizumab in small bowel CD using objective endpoints. Current data suggest that MR …

  • 12 views
  • 28 Jul, 2021
  • 1 location
Clinical Study to Evaluate Efficacy and Safety of ASC and Fibringlue or Fibringlue in Patients With Crohn's Fistula

This is a phase III study to evaluate the efficacy and safety of ASC(Autologous Adipose-derived Stem Cells) and Fibringlue or Fibringlue in Patients With Crohn's Fistula.

  • 0 views
  • 03 Feb, 2021
  • 3 locations
Stopping Aminosalicylate Therapy in Inactive Crohn's Disease

The purpose of this study is to assess whether withdrawal of aminosalicylate (5-ASA) is non-inferior to continuation of 5-ASA therapy in Crohn's disease (CD) subjects in remission.

mesalamine
aminosalicylate
remission
  • 140 views
  • 12 Apr, 2021
  • 49 locations
A Study of E6011 in Participants With Active Crohn's Disease

The primary purpose of this study is to examine the efficacy and safety of E6011 at 12 weeks after administration by means of double-blind placebo-controlled trial.

crohn's disease
mercaptopurine
ulceration
mesalamine
antibiotics
  • 21 views
  • 15 Sep, 2021
  • 125 locations
Efficacy and Safety of TD-1473 in Crohn's Disease

A Phase 2 study to evaluate the efficacy, safety and tolerability of TD-1473 in subjects with moderately-to-severely active Crohn's Disease with up to 48 weeks of treatment.

aminosalicylate
crohn's disease
tumor necrosis factor
mercaptopurine
conventional treatment
  • 318 views
  • 08 Sep, 2021
  • 209 locations
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.

ustekinumab
crohn's disease
  • 652 views
  • 12 Sep, 2021
  • 1004 locations
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)

ileal Crohn's disease. The primary endpoint 6-month endoscopic recurrence. Endpoints - Primary endpoint; 6 months Secondary endpoints at 1 and 5 years post ileocecal resection Study

crohn's disease
tumor necrosis factor
vedolizumab
ustekinumab
thiopurines
  • 0 views
  • 26 Jan, 2021
  • 5 locations
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

ustekinumab exposure (pharmacokinetics [PK]) in pediatric participants with moderately to severely active Crohn's disease.

ileocolitis
fistulising crohn's disease
crohn's disease
ulceration
faecal calprotectin
  • 0 views
  • 08 Sep, 2021
  • 57 locations
Ileal Crohn's Disease and Post-operative Outcome: Prospective Cohort Study of the REMIND Group

Crohn's disease (CD), a chronic inflammatory process in intestinal segments leads to tissue damage. More than two thirds of CD patients need intestinal resection. Symptomatic clinical recurrence

tumour necrosis
tumor necrosis factor
crohn's disease
mercaptopurine
thiopurines
  • 9 views
  • 27 Mar, 2021
  • 17 locations